 AbbVie Inc NYSE: ABBV and Regenxbio Inc NASDAQ: RGNX have partnered to develop and commercialize RGX-314, potential one-time gene therapy for wet age-related macular degeneration wet AMD, diabetic retinopathy DR, and other chronic retinal diseases. RGX-314 is currently being evaluated in patients with wet AMD in a pivotal trial utilizing subretinal delivery and patients with wet AMD and DR in two separate Phase 2 trials using in-office suprachoroidal delivery. 